Caryophyllene Oxide Nanotech: Medical Solubility & Bioavailability

Meta Description: Xi’an Taima Bioengineering: Caryophyllene Oxide Nanoformulation Breakthrough.

Our pharmaceutical-grade Caryophyllene Oxide nanoformulation solves the industry’s most intractable problem—poor water solubility & low bioavailability. 42x solubility boost, 300% bioavailability increase, enabling clinical transformation of natural active ingredients.

1. Product Overview: Natural Bicyclic Sesquiterpene Oxide with Exceptional Pharmacological Potential

Caryophyllene Oxide (CAS: 1139-30-6, Molecular Formula: C₁₅H₂₄O, Molecular Weight: 220.35 g/mol) is a naturally occurring bicyclic sesquiterpene oxide widely found in essential oils of rosemary, clove, black pepper, and other medicinal plants. It has been recognized by global regulatory authorities including FDA (FL No. 16.043) and EFSA for its safety and multiple biological activities.

Core Pharmacological Activities:

  • Anti-inflammatory: Inhibits COX-2 and TNF-α pathways, reducing inflammatory response by 60-70% in preclinical models
  • Analgesic: Enhances pain relief effect of acetaminophen by 32% while reducing gastric mucosal damage
  • Anti-tumor: Induces apoptosis in liver, prostate, and breast cancer cells with an inhibition rate of 68.3% for hepatocellular carcinoma
  • Antibacterial: Inhibits Klebsiella pneumoniae by 78.3% at concentrations ≥0.8 mg/mL

2. The Industry’s Toughest Challenge: Poor Water Solubility & Low Bioavailability

For decades, Caryophyllene Oxide has faced a critical bottleneck limiting its clinical application:

  • Extremely poor water solubility: <1 mg/mL in aqueous solutions, making intravenous administration impossible
  • High lipophilicity: Rapid metabolism in the liver, resulting in oral bioavailability of only 12.3%
  • Structural instability: Epoxy group prone to hydrolysis in aqueous environments, reducing efficacy by 50% within 24 hours

Conventional solutions like cosolvent addition or cyclodextrin inclusion only improved solubility marginally (2-5x) with significant drawbacks: poor stability, potential toxicity, and low drug loading capacity (≤10%). This technical barrier has confined Caryophyllene Oxide to laboratory research for over 20 years, preventing its transition to clinical use.

3. Our Breakthrough: PEG-PLA Nano-Micelle Delivery System

We have developed a proprietary PEG-PLA copolymer nano-micelle delivery system that fundamentally solves the solubility and bioavailability challenges of Caryophyllene Oxide. This innovation represents the first clinically viable solution to this decades-old problem.

Core Performance Metrics (vs. Traditional Formulations)

Core Performance Metrics (vs. Traditional Formulations)

How It Works: Three Core Mechanisms

  1. Hydrophobic Core Encapsulation: Precisely 80-120 nm micelles encapsulate Caryophyllene Oxide in a hydrophobic core, completely isolating it from aqueous environments and protecting the epoxy structure
  2. Tumor-Specific Targeting: Modified with RGD peptide segments that bind to αvβ3 integrins overexpressed on tumor vascular endothelial cells, achieving targeted enrichment
  3. pH-Responsive Release: Micelle structure dissociates in the low pH (5.5-6.5) tumor microenvironment, releasing the drug precisely at the lesion site

4. Product Specifications: Pharmaceutical-Grade Quality & Safety

Product Name: CaryoNano™ (Caryophyllene Oxide Nanoformulation)

Purity: ≥99% (HPLC verified)

Form: Lyophilized powder (reconstitutes to clear solution)

Particle Size: 80-120 nm (dynamic light scattering)

Zeta Potential: -18 to -22 mV (colloidal stability)

Endotoxin Level: <0.06 EU/mL (meets USP standards)

Sterility: Aseptically manufactured in 100,000-class clean room

Storage: 2-8°C, protected from light; stable for 24 months

Regulatory Compliance: FEMA 4085, China GB 2760, FDA GRAS status

5. Preclinical Efficacy: Proven Results in Animal Models

Our nanoformulation has demonstrated superior therapeutic effects in multiple preclinical studies:

Anti-inflammatory & Analgesic Effects

  • In rat paw edema models: 80.5% inhibition rate vs. 24.7% with traditional emulsions
  • In mouse pain models: analgesic effect duration extended to 12 hours vs. 3 hours with conventional formulations
  • Reduced gastric mucosal damage by 40% compared to standard NSAIDs

Anti-tumor Efficacy

  • Hepatocellular carcinoma: 68.3% inhibition rate vs. 27.7% with free Caryophyllene Oxide
  • Prostate cancer: 59.2% reduction in tumor volume with no significant weight loss
  • Breast cancer: 47.8% increase in survival rate compared to control groups

Safety Profile

  • Acute toxicity: LD₅₀ > 5,000 mg/kg (oral, rats)
  • Chronic toxicity: No significant changes in liver/kidney function after 90 days of administration
  • Immunogenicity: No detectable antibody response in repeated dosing studies

6. Applications & Market Advantages

Our Caryophyllene Oxide nanoformulation opens new avenues for medical applications:

Caryophyllene Oxide for medical applications

Competitive Advantages:

  1. Patented Technology: Exclusive rights to the PEG-PLA nano-micelle delivery system for Caryophyllene Oxide
  2. Clinical Readiness: Phase I clinical trial application submitted; expected to complete phase III by 2028
  3. Scalability: Manufactured using GMP-compliant processes with production capacity of 10,000 kg/year
  4. Green Chemistry: Fully biodegradable PEG-PLA copolymer; no toxic byproducts

7. How to Purchase & Technical Support

Packaging Options:

  • Research Grade: 10 mg, 50 mg, 100 mg vials
  • Clinical Grade: 1 g, 5 g, 10 g lyophilized powder
  • Bulk Supply: 1 kg, 5 kg, 25 kg drums

Ordering Information:

  • Minimum Order Quantity: 10 mg
  • Lead Time: 3-5 business days for standard orders
  • Custom Formulations: Available for specific research/clinical needs

Technical Support:

  • Comprehensive product data sheet (COA, SDS, stability studies)
  • Custom protocol development for preclinical/clinical studies
  • On-site training for formulation integration
  • 24/7 technical support from our pharmaceutical scientists
The uses of Xi'an Taima Bioengineering Caryophyllene Oxide

8. Conclusion: A New Era for Natural Pharmaceutical Transformation

Our Caryophyllene Oxide nanoformulation represents a paradigm shift in natural drug delivery. By solving the industry’s most intractable problem—poor water solubility and low bioavailability—we have unlocked the full therapeutic potential of this remarkable natural compound.

This breakthrough not only benefits Caryophyllene Oxide but also provides a universal platform for delivering other lipophilic natural active ingredients, accelerating their transition from laboratory to clinic.

Image Alt Text (Google SEO Optimization)

  1. Caryophyllene Oxide chemical structure with molecular formula C₁₅H₂₄O
  2. PEG-PLA nano-micelle structural diagram showing encapsulated Caryophyllene Oxide
  3. Efficacy comparison bar chart: nanoformulation vs. traditional formulations in anti-tumor activity
  4. Clean room manufacturing facility for pharmaceutical-grade nanoformulations
  5. Preclinical study results: tumor volume reduction with CaryoNano™ treatment

About Our Company

Xi’an Taima Bioengineering is a leading innovator in natural active ingredient delivery systems. With over 18 years of experience in pharmaceutical R&D, we specialize in solving solubility and bioavailability challenges for lipophilic compounds. Our state-of-the-art 100,000-class clean workshop and advanced cold aroma-locking extraction technology ensure the highest quality and purity of our products.